231 (PB219): Optimizing treatment strategies for HER2-positive breast and gastric cancer: preclinical evaluation of disitamab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and their combinations therapies in mouse models
Title:
231 (PB219): Optimizing treatment strategies for HER2-positive breast and gastric cancer: preclinical evaluation of disitamab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and their combinations therapies in mouse models
Author:
Pourjamal, N. Joncour, V. Le Vereb, G. Honkamaki, C. Isola, J. Leyton, J.V. Pirjo, L. Heikki, J. Barok, M.